Drug intelligence / Profile preview

CJ-30044

Development stage: Phase 1
Lead developer: CJ CheilJedang
Modality: Small Molecules
Administration: Oral

Overview

CJ-30044 is a small molecule drug candidate initially developed by CJ CheilJedang and later associated with HK inno.N. It has been evaluated in at least one completed Phase 1 clinical trial involving healthy adult male volunteers, where its safety and pharmacokinetic properties were compared to those of bepotastine besilate. The drug is administered orally. As of the latest available information, there are no approved indications or known mechanisms of action for CJ-30044, and it has not received regulatory approval in any country[1][2].

Beyond the preview

Go deeper on CJ-30044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJ-30044.

Explore the full profile